Android app on Google Play

BioCryst Pharma (BCRX) Posts Narrower than Expected Q1 Loss of 13c/Share; Reaffirms

May 7, 2012 6:32 AM EDT Send to a Friend
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q1 EPS of ($0.13), $0.13 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $5.9 million.

BioCryst Pharmaceuticals, Inc. reaffirmed FY2012 guidance.

For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities


Add Your Comment